In 24 Japanese T2DM patients, once-weekly semaglutide significantly improved vascular endothelial function (RHI 1.62→2.04, p<0.01) independently of concurrent improvements in weight, HbA1c, and LDL cholesterol.
Direct vascular protectionSemaglutide improved endothelial function independently of metabolic improvements—suggesting a direct GLP-1-mediated vascular protective effect beyond glucose and weight control
What the researchers found
RHI: 1.62±0.19 → 2.04±0.60 (p<0.01). BW, HbA1c, LDL-cho also improved (all p<0.01). hsCRP trended down (NS). No correlation between metabolic changes and RHI improvement. 24 patients, mean age 55, 83% male.
Why it matters
Endothelial dysfunction is the earliest step in atherosclerosis. Demonstrating that semaglutide directly improves endothelial function—independent of metabolic improvements—reveals a direct vascular protective mechanism.
How the study worked
Retrospective observational study at Jinnouchi Hospital (Japan). 24 T2DM patients initiated on once-weekly SC semaglutide since 2021. RHI by EndoPAT. Clinical parameters before and after treatment.
What this study cannot tell us
Small sample (24). Retrospective. No control group. Japanese population. RHI has measurement variability. Follow-up duration not specified.
How to read the evidence
Small retrospective observational study. Novel finding but needs larger confirmation.
When this study was published
Published in 2025.
The bigger picture
This adds direct endothelial protection to semaglutide's cardiovascular benefit portfolio. The lack of correlation with metabolic changes suggests a novel, independent vascular mechanism.
Questions still open
- What direct mechanism improves endothelial function independently of metabolic effects?
- Would this translate to reduced atherosclerosis progression on imaging?
- Do other GLP-1 drugs show the same direct vascular effect?
Common questions
Does semaglutide protect blood vessels?
What is endothelial function and why does it matter?
Read the original research
Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.
Cureus, 17(12), e99998
Citation
Sugiyama, Seigo; Yoshida, Akira; Kurinami, Noboru; Hieshima, Kunio; Jinnouchi, Katsunori; Suzuki, Tomoko; Miyamoto, Fumio; Kajiwara, Keizo; Jinnouchi, Hideaki. (2025). Once-Weekly Semaglutide Is Associated With Improvement in Vascular Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study.. Cureus, 17(12), e99998. https://doi.org/10.7759/cureus.99998